 14. 14. Patient has impairment of gastrointestinal GI function or GI disease that may significantly alter the absorption of panobinostat e.g. ulcerative disease, uncontrolled nausea, vomiting, malabsorption syndrome, obstruction, or stomach andor small bowel resection 